A tetrameric protein called transthyretin (TTR), formerly known as thyroxine-binding prealbumin, transports hormones in the brain and plasma. Thyroid hormones and vitamin A are more easily transported in the blood and cerebrospinal fluid thanks to the complex it forms with retinol-binding protein (RBP). TTR has a negative correlation with inflammation and a positive indicator of nutrition status. TTR functions as a neuroprotective and anti-oxidative stress agent. Mutations, oxidative modifications, aging, proteolysis, and metal cations, such as Ca2+, all cause the TTR structure to become unstable. Senile and familial amyloidopathies are caused by amyloid deposits created by destabilized TTR molecules.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V70111 | Acoramidis hydrochloride (AG10 hydrochloride) | 2242751-53-5 | Acoramidis (AG10) HCl is an orally bioactive, selective stabilizer of transthyretin (TTR (transthyretin)), effective against both wild-type and V1221 mutants. |
![]() |
V70112 | Eplontersen sodium | 2131025-75-5 | Eplontersen sodium is a triantennary, N-acetylgalactosamine (GalNAc3)-conjugated antisense oligonucleotide that targets transthyretin TTR mRNA and inhibits variant and wild-type TTR production. |
![]() |
V70110 | Inotersen sodium (ISIS-420915 sodium) | 1432726-13-0 | Inotersen (ISIS-420915) sodium is a 2'-O-methoxyethyl modified antisense oligonucleotide. |
![]() |
V70106 | Patisiran sodium | 1386913-72-9 | Patisiran sodium is a double-stranded small interfering RNA that targets sequences within the Transthyretin (TTR) messenger RNA. |
![]() |
V81150 | PITB | PITB is a selective, orally bioactive inhibitor of transthyretin (TTR) aggregation. | |
![]() |
V4862 | Tafamidis | 594839-88-0 | Tafamidis (also known as Fx-1006 or PF-06291826; Vyndaqel and Vyndamax), a potent and selective transthyretin (TTR)stabilizer, is a medication approved for use in delaying disease progression in adults with certain forms of transthyretin amyloidosis. |
![]() |
V87853 | Transthyretin-IN-2 | 4664-62-4 | Transthyretin-IN-2 (Compound 36) is a transthyretin (TTR) amyloidosis inhibitor with IC50 and pIC50 values of 1.31 μM and 5.88 μM, respectively. |
![]() |
V87852 | Transthyretin-IN-3 | 3008535-20-1 | Transthyretin-IN-3 (compound 6) is a designed benzofuran analog. |
![]() |
V97925 | TTR stabilizer 1 | 2778162-15-3 | TTR stabilizer 1 (Compound 1) is a stabilizer of transthyretin (TTR) with an EC50 value of 0.031 μM. |
![]() |
V70109 | Vutrisiran (ALN-TTRsc02) | 1867157-35-4 | Vutrisiran (ALN-TTRsc02) is a liver-directed, small interfering RNA (siRNA). |
![]() |
V70113 | WT-TTR inhibitor 1 | 23983-05-3 | WT-TTR inhibitor 1 (Compound 21) is an inhibitor (blocker/antagonist) of wild-type transthyretin (WT-TTR) with an inhibition rate of 29.05% at 100 μM. |
![]() |
V14470 | Tafamidis meglumine (Fx1006, PF06291826) | 951395-08-7 | Tafamidismeglumine(formerly Fx-1006; PF-06291826; Vyndaqel and Vyndamax), the meglumine salt of tafamidis, is a potent and selective transthyretin (TTR)stabilizer, is an approved drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. |